Skip to main
COLL
COLL logo

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. has demonstrated robust growth, with a 31% year-over-year increase in net revenue to $209.4 million, surpassing both forecast expectations and consensus estimates. The company's flagship product, Jornay, continues to excel, showing a 20% increase in total prescriptions year-over-year and a notable sequential revenue growth of 28.2%, supported by an improvement in gross-to-net ratios. Furthermore, the positive revisions to 2025 guidance, including raised top-line expectations to $745 million-$760 million and solid contributions from the adult segment, underscore strong market positioning and potential for sustained expansion.

Bears say

Collegium Pharmaceutical Inc. has highlighted several vital concerns that contribute to a negative outlook on its stock, such as a reduction in prescriptions for key products like Xtampza ER and Nucynta, as well as lower sales projections linked to the potential entry of generic competitors. Although operating cash flow reached $78.4 million for the quarter and net leverage improved to approximately 1.2x adjusted EBITDA, risks persist regarding commercialization delays and higher-than-expected expenses, which might hinder profit margins. Additionally, management's goals to reduce net leverage below 1.0x by the end of 2025 could face challenges due to unfavorable reimbursement landscapes and execution risks related to product integration and regulatory compliance.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.